Fast Facts: Biosimilars in Hematology and Oncology

Biologics have revolutionized - and are revolutionizing - the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars - particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. Contents: * Biologics and the need for biosimilars * Why do we need biosimilars? * How is the quality of biosimilar medicines assured? * Legal issues * Switching, interchangeability and extrapolation * Safety and pharmacovigilant * Global issues * Formulary considerations: pharmacy issues * Formulary considerations: supportive care biosimilars * Formulary considerations: therapeutic anti-cancer biosimilars * Communication and awareness